Out of the woods, but still in the weeds: When cancer therapy becomes part of a chronic condition

医学 伊马替尼 狼牙棒 内科学 心肌梗塞 癌症 人口 慢性粒细胞白血病 疾病 魔法子弹 死因 甲磺酸伊马替尼 肿瘤科 外科 白血病 生物信息学 环境卫生 髓系白血病 传统PCI 生物
作者
Kathleen W. Zhang
出处
期刊:Heart [BMJ]
卷期号:107 (8): 607-608 被引量:1
标识
DOI:10.1136/heartjnl-2020-318692
摘要

Imatinib was introduced on the cover of TIME magazine in 2001 as ‘the magic bullet’ to cure cancer, ushering in a new era of targeted cancer therapeutics that has transformed the modern landscape of cancer treatment. As the first tyrosine kinase inhibitor (TKI) targeting the Bcr-Abl protein, imatinib revolutionised the treatment of chronic myelogenous leukaemia (CML) by improving 10-year survival from 20% to 90%.1 In patients who achieve complete cytogenetic remission on imatinib, overall survival with CML is now comparable to that of population-based controls.2 Due to this metamorphosis from devastating diagnosis to chronic illness, better understanding of non-cancer-related morbidity and mortality is needed in patients with CML on long-term TKI therapy. In this issue of Heart , Leong et al 3 examined the incidence of major adverse cardiovascular events (MACE) and cardiovascular mortality in 4238 patients with CML from Ontario, Canada between 1986 and 2017, as compared with an age-matched and sex-matched control group. Separate analyses were performed for patients diagnosed before and after the introduction of TKIs in 2001. MACE was defined as hospitalisation for myocardial infarction, cerebrovascular disease or peripheral arterial disease using administrative codes, while cardiovascular death was determined by the physician certifying the patient’s death. Among 46 618 patients included in the study, the authors found increased risk of all-cause mortality in the patients with CML that was attenuated post-TKIs, consistent with known improvement in overall survival on TKI therapy. While risks of MACE and cardiovascular mortality were lower in the patients with CML pre-TKIs, there were no differences between the CML and control groups post-TKIs. In fact, the risk of peripheral arterial disease was higher in the patients with CML post-TKIs (HR=1.66 (95% CI 1.15 to …
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
完美世界应助dxx采纳,获得10
1秒前
1秒前
Lyn应助好丫水果采纳,获得30
1秒前
飞快的小松鼠完成签到,获得积分10
1秒前
燕山黑驴发布了新的文献求助10
2秒前
1122发布了新的文献求助10
3秒前
欣喜亚男发布了新的文献求助10
3秒前
ETJ完成签到,获得积分10
3秒前
隐形曼青应助ly采纳,获得10
3秒前
4秒前
卖鱼拙然发布了新的文献求助10
4秒前
林一木完成签到,获得积分10
4秒前
完美世界应助lululululululu采纳,获得10
4秒前
Kent完成签到,获得积分10
5秒前
科研通AI2S应助典雅睿渊采纳,获得30
6秒前
6秒前
水边的竹完成签到,获得积分10
6秒前
小马甲应助苗松采纳,获得10
6秒前
7秒前
zeroayanami0完成签到,获得积分10
7秒前
关掉子完成签到,获得积分10
8秒前
怕黑的店员完成签到 ,获得积分10
8秒前
饿m完成签到 ,获得积分10
9秒前
9秒前
乐乐乐乐乐乐应助库三金采纳,获得10
10秒前
VPN不好用发布了新的文献求助10
10秒前
一一发布了新的文献求助10
10秒前
10秒前
欧阳发布了新的文献求助10
11秒前
11秒前
桐桐应助辅助成灾采纳,获得10
11秒前
快乐水发布了新的文献求助10
11秒前
落后的冬天完成签到,获得积分10
11秒前
11秒前
Jasper应助Nilzz采纳,获得10
11秒前
11秒前
勤奋的晓晓应助畅快的枫采纳,获得10
12秒前
12秒前
燕山黑驴完成签到,获得积分10
13秒前
高分求助中
The late Devonian Standard Conodont Zonation 2000
Nickel superalloy market size, share, growth, trends, and forecast 2023-2030 2000
The Lali Section: An Excellent Reference Section for Upper - Devonian in South China 1500
Very-high-order BVD Schemes Using β-variable THINC Method 870
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 800
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 800
Fundamentals of Dispersed Multiphase Flows 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3254704
求助须知:如何正确求助?哪些是违规求助? 2896919
关于积分的说明 8295019
捐赠科研通 2565930
什么是DOI,文献DOI怎么找? 1393400
科研通“疑难数据库(出版商)”最低求助积分说明 652526
邀请新用户注册赠送积分活动 630091